The comeback kid: TYSABRI now FDA approved for Crohn disease

The comeback kid: TYSABRI now FDA approved for Crohn disease.

The Journal of Clinical Investigation http://www.jci.org Volume 118 Number 3 March 2008 825 The comeback kid: TYSABRI now FDA approved for Crohn disease The US FDA recently approved the monoclonal antibody TYSABRI (natalizumab) for use in the treatment of adults with moderately to severely active Crohn disease (CD) who do not respond to, or do not tolerate, conventional therapies for CD and inh...

The Comeback Kid?

Balloon angioplasty revolutionized coronary revascularization; however, elastic recoil and restenosis caused by cellular proliferation are major drawbacks of angioplasty. Intracoronary stenting, which could tackle dissections and eliminate elastic recoil, became the next mode of intervention but was limited by stent thrombosis and increased neointimal hyperplasia, leading to in-stent restenosis...

Potential Vaccines for Treating Crohn\'s Disease

Crohn's disease (CD) is an inflammatory disease of the gastrointestinal tract (GIT) tract and can affect several parts of the digestive system. There is a relationship between impaired mucosal barrier in the GIT of inflammatory bowel disease patients and the role of bacteria such as Mycobacterium avium paratuberculosis in CD. Apart from different therapeutic approaches for treating CD, developm...

FDA approved drugs repurposing of Toll-like receptor4 (TLR4) candidate for neuropathy

Accumulating evidence indicates that toll-like receptor 4 (TLR4) plays a critical role in promoting adaptive immune responses and are definitively involved in the expansion and maintenance of the neuropathic pain. However, the application of docking in virtual-screening in silico methods to drug discovery has some challenge but it allows us to make the directed and meaningful design of drugs fo...

FDA-Approved Drugs to Treat Schizophrenia.